Nick Finer
Nick Finer
Novo Nordisk and UCL, London
Verified email at
Cited by
Cited by
Effect of sibutramine on weight maintenance after weight loss: a randomised trial*
WPT James, A Astrup, N Finer, J Hilsted, P Kopelman, S Rössner, ...
The Lancet 356 (9248), 2119-2125, 2000
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
WPT James, ID Caterson, W Coutinho, N Finer, LF Van Gaal, ...
New England Journal of Medicine 363 (10), 905-917, 2010
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
AJ Scheen, N Finer, P Hollander, MD Jensen, LF Van Gaal
The lancet 368 (9548), 1660-1672, 2006
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A Astrup, R Carraro, N Finer, A Harper, M Kunesova, MEJ Lean, ...
International journal of obesity 36 (6), 843-854, 2012
Management of obesity in adults: European clinical practice guidelines
C Tsigos, V Hainer, A Basdevant, N Finer, M Fried, E Mathus-Vliegen, ...
Obesity facts 1 (2), 106-116, 2008
Redefining type 2 diabetes:‘diabesity’or ‘obesity dependent diabetes mellitus’?
A Astrup, N Finer
obesity reviews 1 (2), 57-59, 2000
Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES)
S Sauerland, L Angrisani, M Belachew, JM Chevallier, F Favretti, N Finer, ...
Surgical endoscopy 19 (2), 200-221, 2005
Inter-disciplinary European guidelines on surgery of severe obesity
M Fried, V Hainer, A Basdevant, H Buchwald, M Deitel, N Finer, ...
International Journal of obesity 31 (4), 569-577, 2007
One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
N Finer, WP James, PG Kopelman, ME Lean, G Williams
International journal of obesity and related metabolic disorders: journal of …, 2000
A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism
WM Kong, MH Sheikh, PJ Lumb, DB Freedman, M Crook, CJ Doré, ...
The American journal of medicine 112 (5), 348-354, 2002
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double‐blind, placebo‐controlled study
N Finer, SR Bloom, GS Frost, LM Banks, J Griffiths
Diabetes, Obesity and Metabolism 2 (2), 105-112, 2000
Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline
EMH Mathus-Vliegen, A Basdevant, N Finer, V Hainer, H Hauner, D Micic, ...
Obesity facts 5 (3), 460-483, 2012
Interdisciplinary European guidelines for surgery for severe (morbid) obesity
M Fried, V Hainer, A Basdevant, H Buchwald, M Deitel, N Finer, ...
Obesity Surgery 17 (2), 260-270, 2007
Interdisciplinary European guidelines on surgery of severe obesity
M Fried, V Hainer, A Basdevant, H Buchwald, M Deitel, N Finer, JW Greve, ...
Obesity facts 1 (1), 52-59, 2008
Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non …
A Yousseif, J Emmanuel, E Karra, Q Millet, M Elkalaawy, AD Jenkinson, ...
Obesity surgery 24 (2), 241-252, 2014
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension
J Jordan, V Yumuk, M Schlaich, PM Nilsson, B Zahorska-Markiewicz, ...
Journal of hypertension 30 (6), 1047-1055, 2012
Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children
E Falaschetti, AD Hingorani, A Jones, M Charakida, N Finer, P Whincup, ...
European heart journal 31 (24), 3063-3072, 2010
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial
C Torp-Pedersen, I Caterson, W Coutinho, N Finer, L Van Gaal, ...
European Heart Journal 28 (23), 2915-2923, 2007
Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA
M Lopez, CJ Lelliott, S Tovar, W Kimber, R Gallego, S Virtue, M Blount, ...
Diabetes 55 (5), 1327-1336, 2006
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial
DL Hansen, A Astrup, S Toubro, N Finer, P Kopelman, J Hilsted, ...
International journal of obesity 25 (4), 496-501, 2001
The system can't perform the operation now. Try again later.
Articles 1–20